KCT0006785
Completed
未知
Open-label, multicenter phase II study of imatinib mesylate (Leukivec®) in patients with steroid-refractory chronic graft-versus-host disease
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Kyungpook National University Hospital
- Enrollment
- 39
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •i) age \= 20 years,
- •ii) Eastern Cooperative Oncology Group performance status score \= 2,
- •iii) Chronic graft\-versus host disease that meets the NIH diagnostic criteria after allogeneic\-SCT,
- •iv) moderate or severe cGVHD based on the NIH global scoring system,
- •v) steroid\-refractory cGVHD,
- •vi) resistance to calcineurin inhibitors such as cyclosporine and tacrolimus
Exclusion Criteria
- •1\. Hepatic chronic graft\-versus host disease alone
- •2\. Patients who had donor lymphocyte infusion
- •3\. Poor general condition
- •4\. ECOG \> 3
- •5\. Other investigational agent treatment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
An open-label multicenter phase II study of Imatinib mesylate (Glivec) treatment of patients with malignant peripheral nerve sheath tumorsmalignant nerve sheath tumorEUCTR2005-004774-24-DEovartis Pharma GmbH
Active, not recruiting
Phase 1
A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)unresectable metastatic GISTMedDRA version: 20.0 Level: LLT Classification code 10062427 Term: Gastrointestinal stromal tumor System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10051066 Term: Gastrointestinal stromal tumour System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-001298-42-GBEuropean Organisation for Research and Treatment of Cancer76
Active, not recruiting
Not Applicable
A randomised phase II trial of imatinib alternating withregorafenib compared to imatinib alone for the first linetreatment of advanced gastrointestinal stromal tumour (GIST)unresectable metastatic GISTMedDRA version: 18.0Level: LLTClassification code 10062427Term: Gastrointestinal stromal tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-001298-42-ESEuropean Organisation for Research and Treatment of Cancer240
Recruiting
Phase 2
A randomised phase II trial of imatinib alternating with;regorafenib compared to imatinib alone for the first line ;treatment of advanced gastrointestinal stromal tumour (GIST)gastrointestinal stromal tumourGIST10072990NL-OMON56311European Organisation for Research in Treatment of Cancer (EORTC)18
Active, not recruiting
Phase 1
A randomised phase II trial of imatinib alternating withregorafenib compared to imatinib alone for the first linetreatment of advanced gastrointestinal stromal tumour (GIST)EUCTR2015-001298-42-FREuropean Organisation for Research and Treatment of Cancer240